Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "EU"

6754 News Found

GlaxoSmithkline Pharmaceuticals appoints Carson Dalton as Executive VP - Communications and Government Affairs
People | March 04, 2025

GlaxoSmithkline Pharmaceuticals appoints Carson Dalton as Executive VP - Communications and Government Affairs

Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability


Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy’s Laboratories
News | March 04, 2025

Senores Pharmaceuticals acquires 14 ANDAs from Dr. Reddy’s Laboratories

The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA


Glenmark Pharmaceuticals acquires and launches acetylcysteine injection
News | March 03, 2025

Glenmark Pharmaceuticals acquires and launches acetylcysteine injection

Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA


Senores Pharmaceuticals begins operations at greenfield API facility
News | February 27, 2025

Senores Pharmaceuticals begins operations at greenfield API facility

This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.


Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
News | February 27, 2025

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies


Glenmark Pharmaceuticals USA launches Epinephrine Injection USP
News | February 27, 2025

Glenmark Pharmaceuticals USA launches Epinephrine Injection USP

This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.


European Commission approves Biocon Biologics' Ustekinumab Biosimilar
News | February 21, 2025

European Commission approves Biocon Biologics' Ustekinumab Biosimilar

YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease